Market research
SAGE Sage Therapeutic
NASDAQ USD Healthcare
Latest close
As of 10 Aug 2025
Test a moving-average rule with historical data.
Market facts
- Market cap
- 545M
- P/E ratio
- Not available
- Analyst target
- 8.5833
- Beta
- Not available
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 545M
- P/E ratio
- Not available
- Analyst target
- 8.5833
- Beta
- Not available
About
About Sage Therapeutic
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. The company offers ZURZUVAE, a neuroactive steroid positive allosteric modulator of GABA receptors targeting synaptic and extrasynaptic GABA receptors for the treatment of postpartum depression in adults. Its product pipeline also includes SAGE-324, a novel GABA receptor positive allosteric modulator for chronic oral dosing, including seizures in developmental and epileptic encephalopathies; and SAGE-319, an extrasynaptic-preferring GABA receptor positive allosteric modulator PAM for treating behavioral symptoms associated with neurodevelopmental disorders. In addition, the company is developing various product candidates, including SAGE-817 and SAGE-039 for the treatment of acute and chronic brain health disorders, including work on allosteric modulation of the GABA and NMDA receptor systems in the brain, as well as NMDA receptor negative allosteric modulator focusing on the treatments for neurodevelopmental disorders. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. As of July 31, 2025, Sage Therapeutics, Inc. operates as a subsidiary of Saphire, Inc.
Research context
Sage Therapeutic appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the SAGE discussion.
5 years, 6 months ago
Sage Therapeutics, Inc is currently in a long term downtrend where the price is trading 27.5% below its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.7.
Sage Therapeutics, Inc's total revenue rose by 56491.1% to $1B since the same quarter in the previous year.
Its net income has increased by 678.0% to $975M since the same quarter in the previous year.
Finally, its free cash flow grew by 963.3% to $1B since the same quarter in the previous year.
Based on the above factors, Sage Therapeutics, Inc gets an overall score of 4/5.